Design, synthesis, and structure-activity relationships of the first highly potent, selective, and bioavailable adenosine5′-monophosphate deaminase inhibitors

被引：0

作者：

Kasibhatla, SR ^{[1
]}

Bookser, BC ^{[1
]}

Appleman, JR ^{[1
]}

Probst, G ^{[1
]}

Xiao, W ^{[1
]}

Fujitaki, JM ^{[1
]}

Erion, MD ^{[1
]}

机构：

[1] Metabasis Therapeut Inc, San Diego, CA 92121 USA

来源：

PURINE AND PYRIMIDINE METABOLISM IN MAN IX | 1998年 / 431卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：849 / 852

页数：4

共 50 条

[1] Design and synthesis of the first potent, selective, and cell penetrating adenosine 5′-monophosphate deaminase inhibitors
Bookser, BC
Kasibhatla, SR
Appleman, JR
Erion, MD
PURINE AND PYRIMIDINE METABOLISM IN MAN IX, 1998, 431 : 853 - 857
[2] Design, synthesis, and sar of the first highly potent, selective and cell-penetrable adenosine 5′-monophosphate deaminase inhibitors.
Kasibhatla, SR
Bookser, BC
Probst, G
Xiao, W
Appleman, JR
Erion, MD
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 218 : U916 - U916
[3] Design of AMP mimetics that are the first highly potent, selective and penetrating inhibitors of adenosine 5'-monophosphate deaminase.
Kasibhatla, SR
Bookser, BC
Probst, G
Appleman, JR
Erion, MD
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 214 : 78 - MEDI
[4] Structure-activity relationships of adenosine deaminase inhibitors
Vittori, S
Camaioni, E
Costanzi, S
Volpini, R
Lupidi, G
Cristalli, G
NUCLEOSIDES & NUCLEOTIDES, 1999, 18 (4-5): : 741 - 742
[5] STRUCTURE-ACTIVITY RELATIONSHIPS IN ADENOSINE DEAMINASE INHIBITORS
SCHAEFFE.HJ
JOHNSON, RN
ODIN, E
HANSCH, C
JOURNAL OF MEDICINAL CHEMISTRY, 1970, 13 (03) : 452 - &
[6] The design and synthesis of inhibitors of adenosine 5′-monophosphate deaminase
Lindell, SD
Moloney, BA
Hewitt, BD
Earnshaw, CG
Dudfield, PJ
Dancer, JE
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (14) : 1985 - 1990
[7] Parallel synthesis and structure-activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitors
Bauer, SM
Goldman, EA
Huang, WR
Su, T
Wang, LY
Woolfrey, J
Wu, YH
Zuckett, JMF
Arfsten, A
Huang, B
Kothule, J
Lin, J
May, B
Sinha, U
Wong, PW
Hutchaleelaha, A
Scarborough, RM
Zhu, BY
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (15) : 4045 - 4050
[8] Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors
Terasaka, T
Okumura, H
Tsuji, K
Kato, T
Nakanishi, I
Kinoshita, T
Kato, Y
Kuno, M
Seki, N
Naoe, Y
Inoue, T
Tanaka, K
Nakamura, K
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (11) : 2728 - 2731
[9] Design and structure activity relationships of highly potent and bioavailable imidazolinone FASN KR domain inhibitors
Bignan, G.
Alexander, R.
Bischoff, J.
Connolly, P.
Cummings, M.
De Breucker, S.
Esser, N.
Fraiponts, E.
Gilissen, R.
Grasberger, B.
Janssens, B.
Lu, T.
Ludovici, D.
Meerpoel, L.
Meyer, C.
Parker, M.
Peeters, D.
Rocaboy, C.
Schubert, C.
Smans, K.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : 141 - 142
[10] Inhibitors of adenosine deaminase: Continued studies of structure-activity relationships in analogues of coformycin
Reayi, A
Hosmane, RS
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2004, 23 (1-2): : 263 - 271

← 1 2 3 4 5 →